ERBB2 and breast cancer: Retrospective studies have shown that metformin use is associated with improved breast cancer-specific survival of diabetic women with luminal [38] and HER2+ breast cancers [39], but did not significantly impact survival outcomes in diabetic patients with triple-negative breast cancer [46].